2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC)

2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC)

NANJING, China and GAITHERSBURG, Md., Dec. 9, 2024 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to discuss the clinical...

QNAP Announces Short-Depth Rackmount NAS TS-433eU with NPU Acceleration and Dual 2.5GbE

QNAP Announces Short-Depth Rackmount NAS TS-433eU with NPU Acceleration and Dual 2.5GbE

TAIPEI, Dec. 9, 2024 /PRNewswire/ -- QNAP® Systems, Inc., a leading computing and storage solutions innovator, today unveiled the compact 1U rackmount 4-bay NAS TS-433eU, which offers small to midsize businesses and organizations an affordable edge...

Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024

Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024

SAN FRANCISCO and SUZHOU, China, Dec. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and...

TraceLink Honored on Inc.'s 2024 Best in Business List

TraceLink Honored on Inc.'s 2024 Best in Business List

Recognized in the Manufacturing Category for Driving Innovation and Excellence in Supply Chain Solutions BOSTON, Dec. 6, 2024 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration,...

CNEY Entered into Warrant Inducement Agreements with Certain Holders

CNEY Entered into Warrant Inducement Agreements with Certain Holders

LISHUI, China, Dec. 5, 2024 /PRNewswire/ -- CN Energy Group. Inc. (NASDAQ: CNEY) ("CNEY" or the "Company") today announced that it entered into Warrant Inducement Agreements with certain holders (each, a "Holder") of the Company's existing ordinary...

SS&C to Present at Abu Dhabi Finance Week

SS&C to Present at Abu Dhabi Finance Week

WINDSOR, Conn., Dec. 5, 2024 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC), a global provider of software and software-enabled services for the financial services and healthcare industries, today announced that Bill Stone,...

ReTo Secured Production Line Contract with Middle Eastern Client

ReTo Secured Production Line Contract with Middle Eastern Client

BEIJING, Dec. 4, 2024 /PRNewswire/ -- ReTo Eco-Solutions, Inc. (Nasdaq: RETO) ("ReTo" or the "Company"), a provider of technology solutions and operation services for intelligent ecological environments and Internet of Things technology development...

Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer

Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer

HONG KONG, Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (AK104-IIT-018) of cadonilimab (PD-1/CTLA-4 bispecific...

CNEY Receives NASDAQ Minimum Bid Price Requirement Extension

CNEY Receives NASDAQ Minimum Bid Price Requirement Extension

LISHUI, China, Dec. 4, 2024 /PRNewswire/ -- CN Energy Group. Inc. (NASDAQ: CNEY) ("CNEY" or the "Company") today announced that on November 26, 2024, the Company received a written notice from the Listing Qualifications Staff of The Nasdaq Stock...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • menu
    menu